echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Medical leader" Internet hospital will break the 100 billion mark, China's approved anti-cancer drugs grand summary

    "Medical leader" Internet hospital will break the 100 billion mark, China's approved anti-cancer drugs grand summary

    • Last Update: 2020-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020 / 01 / 08) in 2020, the Internet hospital will break the 100 billion mark, but there are three problems to be solved; after Hengrui, the "celecoxib capsule" of Zhengda Qingjiang is approved; carrying 21 bottles of cancer cell doctor of medicine may face the disaster of imprisonment; details of large-scale M & a transactions of global pharmaceutical enterprises in 2019 If approved, pemigatinib will be the first targeted therapy for cholangiocarcinoma in Europe Close behind If sentenced, up to 10 years Nmpa is working The year of M & A Internet changes consultation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.